Citation Impact
Citing Papers
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
2013 StandoutNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
2005 Standout
Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study
2006
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Mechanisms of type-I- and type-II-interferon-mediated signalling
2005 Standout
Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen‐negative patients
1998
Hepatitis B Virus Infection — Natural History and Clinical Consequences
2004 Standout
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B
2000
Primary liver cancer: Worldwide incidence and trends
2004 Standout
Hepatic Disorders
1995
Pathogenesis of hepatitis B virus infection
2010
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study
2002
A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients
2005
Hepatitis B Virus Infection: Epidemiology and Vaccination
2006 Standout
A robust cell culture system supporting the complete life cycle of hepatitis B virus
2017 StandoutNobel
Burden of liver diseases in the world
2018 Standout
Liver fibrosis – from bench to bedside
2003 Standout
Natural history of chronic hepatitis B virus infection: An immunopathological study
1997
Molecular biology of hepatitis B virus e antigen
1997
Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen‐negative chronic hepatitis B virus‐infected patients
2002
Cytotoxic T cells and viral hepatitis.
1997
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C
2002
Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity
2000
Immunology of hepatitis B virus and hepatitis C virus infection
2005 Standout
Hepatitis B virus infection
2009 Standout
Chronic hepatitis B
2001
Evidence for a dynamic host‐parasite relationship in e‐negative hepatitis B carriers
2002
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
2005 Standout
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
2004 Standout
Hepatitis B e antigen-negative chronic hepatitis B
2001
Hepatitis B virus genotypes in the United States: results of a nationwide study
2003
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Treatment of chronic hepatitis B
2001
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Hepatitis B e antigen-negative chronic hepatitis b in Hong Kong
2000
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
2004 Standout
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.
1996 StandoutNobel
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
2004 Standout
A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals
2000
Mutations in the Basic Core Promotor and the Precore Region of Hepatitis B Virus and Their Selection in Children With Fulminant and Chronic Hepatitis B
1999
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
2006 Standout
Chronic hepatitis B
2007 Standout
The natural history of chronic hepatitis B virus infection #
2009
Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B
2001
The Natural Course of Chronic Hepatitis B Virus Infection and Its Management
2013
Chronic hepatitis B: Update 2009 #
2009 Standout
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
2012 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Expression of activation-induced cytidine deaminase in human hepatocytes via NF-κB signaling
2007 StandoutNobel
Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma
2008
Efficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Bb
1999
Outcome of Hepatitis B e Antigen–Negative Chronic Hepatitis B on Long-Term Nucleos(t)ide Analog Therapy Starting With Lamivudine *
2005
Hepatitis B virus variants
2009
Regulation of type I interferon responses
2013 Standout
Genomic Analysis Reveals a Potential Role for Cell Cycle Perturbation in HCV-Mediated Apoptosis of Cultured Hepatocytes
2009 StandoutNobel
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438.
2003
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen
2000
Prevalence of Hbv Precore/Core Promoter Variants in the United States
2003
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
2002 Standout
Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
2000
Exploring the Biological Basis of Hepatitis B E Antigen in Hepatitis B Virus Infection
2003
Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
2015 StandoutNobel
Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens
2015 StandoutNobel
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D
2005
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
2006
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Hepatitis B virus induces RNR-R2 expression via DNA damage response activation
2015 StandoutNobel
Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Advanced Liver Disease in HBeAg-Negative Patients
2007
Hepatocellular Carcinoma
2011 Standout
Long Term Response to Therapy of Chronic Anti-Hbe–Positive Hepatitis B Is Poor Independent of Type and Schedule of Interferon
1999
Reactivation of hepatitis B virus with rituximab
2005
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview
2003
A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen
2004
Long term response to therapy of chronic anti-HBe–positive Hepatitis B is poor independent of type and schedule of interferon
1999
Sexually Transmitted Diseases Treatment Guidelines, 2010
2011 Standout
Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium
2000
Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine.
2006 Standout
The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B
1999
Vaccinating HIV patients: focus on human papillomavirus and herpes zoster vaccines.
2013 StandoutNobel
Precore Stop Mutant in HBeAg-Positive Patients with Chronic Hepatitis B: Clinical Characteristics and Correlation with the Course of HBeAg-to-Anti-HBe Seroconversion
2002
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease
2000 Standout
IMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS
2006
Stealth and Cunning: Hepatitis B and Hepatitis C Viruses
2005
Response of pre-core mutant chronic hepatitis B infection to lamivudine
2000
HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C
2002
Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B
2000
Activation of the grp78 and grp94 Promoters by Hepatitis C Virus E2 Envelope Protein
1999 StandoutNobel
A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin
2014 Standout
The immune response during hepatitis B virus infection
2006
Rapid and Sensitive Assays for Determination of Hepatitis B Virus (HBV) Genotypes and Detection of HBV Precore and Core Promoter Variants
2003
New Methods in Tissue Engineering: Improved Models for Viral Infection
2014 StandoutNobel
Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic
1996
Liver-Derived CTL in Hepatitis C Virus Infection: Breadth and Specificity of Responses in a Cohort of Persons with Chronic Infection
1998 StandoutNobel
Works of M. Giarin being referenced
Quantitative analysis of wild‐type and HBeAg minus hepatitis B viruses by a sequence‐dependent primer extension assay
1994
‘e’ Antigen defective hepatitis B virus and course of chronic infection
1991
Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
1993
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
1991